These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18690502)

  • 1. Cyclophosphamide-based combination therapies for autoimmunity.
    Perini P; Calabrese M; Rinaldi L; Gallo P
    Neurol Sci; 2008 Sep; 29 Suppl 2():S233-4. PubMed ID: 18690502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.
    Boster A; Edan G; Frohman E; Javed A; Stuve O; Tselis A; Weiner H; Weinstock-Guttman B; Khan O;
    Lancet Neurol; 2008 Feb; 7(2):173-83. PubMed ID: 18207115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
    Patti F; Reggio E; Palermo F; Fiorilla T; Politi G; Nicoletti A; Reggio A
    J Neurol; 2004 Dec; 251(12):1502-6. PubMed ID: 15645351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F; Kieseier BC
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract]   [Full Text] [Related]  

  • 6. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis.
    Jeffery DR
    Neurology; 2004 Dec; 63(12 Suppl 6):S41-6. PubMed ID: 15623670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
    J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
    Yeh EA; Weinstock-Guttman B
    Neurology; 2009 Jun; 72(24):2064-5. PubMed ID: 19439721
    [No Abstract]   [Full Text] [Related]  

  • 10. Concomitant therapy for multiple sclerosis.
    Stuart WH; Vermersch P
    Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 12. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
    Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
    J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclophosphamide therapy in pediatric multiple sclerosis.
    Makhani N; Gorman MP; Branson HM; Stazzone L; Banwell BL; Chitnis T
    Neurology; 2009 Jun; 72(24):2076-82. PubMed ID: 19439723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influences on cognition by immunosuppression and immunomodulation in multiple sclerosis.
    Tumani H; Uttner I
    J Neurol; 2007 May; 254 Suppl 2():II69-72. PubMed ID: 17503133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies.
    Giovannoni G
    Neurology; 2003 Nov; 61(9 Suppl 5):S13-7. PubMed ID: 14610104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroids treatment.
    Pozzilli C; Marinelli F; Romano S; Bagnato F
    J Neurol Sci; 2004 Aug; 223(1):47-51. PubMed ID: 15261560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical markers of therapeutic response to disease modifying drugs.
    Pozzilli C; Prosperini L
    Neurol Sci; 2008 Sep; 29 Suppl 2():S211-3. PubMed ID: 18690494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.